Jorge Sanchez, MD, MPH
Jorge Sanchez, MD, MPH (Faculty Mentor) is an internationally recognized expert in the field of HIV and STI clinical trials in Latin America. As Principal Investigator of the ACTG clinical trials unit at IMPACTA, he has developed and participated in protocols for the NIH-sponsored HIV Prevention Trials (HPTN), HIV Vaccine Trials (HVTN), and the AIDS Clinical Trial Group (ACTG) networks. He is currently affiliated with the Centro de Investigaciones Tecnologicas, Biomedicas y Medioambientales where he is responsible for conceptualization and execution of new research concepts for HIV and STI surveillance, treatment, and prevention among MSM/TW in Latin America.
Optimization of antiretroviral therapy in developing country settings
HIV/STI surveillance in MSM populations
Beyer C, Sullivan P, Millett G, Sanchez J, Baral SD, Collins C, Wirtz AL, Altman D, Trapence G, Mayer K. The increase in global HIV epidemics in MSM. AIDS. 2013 Nov 13;27(17):2665-78.
Sullivan PS, Carballo-Diéguez A, Coates T, Goodreau SM, McGowan I, Sanders EJ,Smith A, Goswami P, Sanchez J. Successes and challenges of HIV prevention in men who have sex with men. Lancet. 2012 Jul 28;380(9839):388-99.
Sanchez J, Sal y Rosas V, Hughes J, Baeten J, Fuchs J, Buchbinder S, Koblin B, Casapia M, Ortiz A, Celum C, Male circumcision and risk of HIV acquisition among men who have sex with men. AIDS. 2011 Feb 20;25(4):519-23.
Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlww S, Cowam F, Casapia M, Ortiz A, Fuchs J, Buchbinder S, Koblin B, Zwerski S, Rose S, Wang J, Corey L, HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Jun 21;371(9630):2109-19.